knowledge -WSS

knowledge

author：leisure time 2025-08-29 01:53:31 - browse：57187

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum. It’s not too late to join us virtually. Check out details here.

It’s a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I’d call a biotech cult stock.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Sen. Paul opposes bill to ban Chinese biotechs

WSS

Texas Department of Public Safety speaks out on migrant abuse allegations

Hospitals struggle to profit from CAR

7 more heat

Stanford president faces new allegations over 1999 paper

Awakening the world to the whoosh: A patient's crusade

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Awakening the world to the whoosh: A patient's crusade

Continuity nursing helped my family in our darkest PICU moments

The problem with charging patients to message their doctors

DIEP, the 'gold standard' of breast reconstruction, is under threat

EF3 tornado rips through North Carolina amid extreme weather nationwide

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Tocagen's brain cancer gene therapy trial continues. Investors worry

Wikipedia

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Indian pharmaceutical industry in denial over drug

Sen. Paul opposes bill to ban Chinese biotechs

Change Healthcare payments predicted restored March 15

With psoriasis trial ahead, Alumis raises $259 million

Novo Nordisk obesity pill bests Wegovy in early trial

entertainment

Wikipedia

focus

leisure time